Hartman T, Carlsson J
Department of Radiation Sciences, Uppsala University, Sweden.
Radiother Oncol. 1994 Apr;31(1):61-75. doi: 10.1016/0167-8140(94)90414-6.
Boron neutron capture therapy, BNCT, might be a valuable tumour therapeutical modality for the treatment of cells that are difficult to handle with conventional methods such as surgery or external radiotherapy. The principle is that tumour associated 10B atoms capture thermal neutrons and thereby forms high-LET helium and lithium ions as reaction products. An interesting development is to conjugate 10B atoms to macromolecules that bind to tumour cells with over-expressed receptors or specific antigens. The targeting macromolecules might be receptor-ligands, antibodies or antibody-fragments containing 10B. The present study deals with the limitations of such an approach. One problem is the background dose from capture of neutrons in physiologically occurring elements, especially nitrogen. We showed, with computer simulations, that the background specific energy (the stochastic analogy of dose) in the cell nuclei, due to captures in nitrogen, had a wide spread and could be rather high, up to 3 Gy in some cells, when relevant neutron fluencies were applied. The maximal amount of 10B that can be delivered to single tumour cells due to receptor-ligand, receptor-antibody or antigen-antibody mediated binding is probably in the range 10(8)-10(10) atoms/cell. Our calculations showed that the tumour cells had to contain about 10(9) 10B/cell to give a therapeutically interesting dose to the nuclei of the targeted cells. The doses were highest when the boron was in the cell nucleus. There was also a wide spread of specific energy absorbed by the nuclei after neutron capture in 10B. When, for example, 10(8) 10(10)B/nucleus were applied the specific energy to the analysed nuclei varied from 0 Gy up to about 7 Gy. These variations were due to the stochastic nature of the capture processes. Some helium or lithium ion tracks passed through the centre of the cell nuclei delivering a lot of energy, some passed through only a smaller part delivering small amounts of energy and sometimes the nuclei escaped without any hits at all. The results were obtained when relevant neutron fluencies (2-5 x 10(12) n/cm2) were applied. Increased neutron fluencies gave higher doses both due to capture in boron and in nitrogen but in order to improve the ratio between the dose to targeted tumour cells and the dose to normal cells, the number of 10B atoms in the targeted cells had to be increased and/or the boron placed in the cell nuclei.
硼中子俘获疗法(BNCT)可能是一种有价值的肿瘤治疗方式,可用于治疗难以用手术或外部放射疗法等传统方法处理的细胞。其原理是肿瘤相关的硼 - 10原子俘获热中子,从而形成高传能线密度的氦离子和锂离子作为反应产物。一个有趣的进展是将硼 - 10原子与能与过表达受体或特异性抗原结合的肿瘤细胞的大分子偶联。靶向大分子可能是受体 - 配体、抗体或含硼 - 10的抗体片段。本研究探讨了这种方法的局限性。一个问题是生理存在元素(尤其是氮)俘获中子产生的本底剂量。我们通过计算机模拟表明,由于氮俘获,细胞核中的本底比能(剂量的随机类似物)分布广泛且可能相当高,当应用相关中子注量时,某些细胞中可达3戈瑞。由于受体 - 配体、受体 - 抗体或抗原 - 抗体介导的结合,可递送至单个肿瘤细胞的硼 - 10的最大量可能在10⁸ - 10¹⁰个原子/细胞范围内。我们的计算表明,肿瘤细胞必须含有约10⁹个硼 - 10/细胞,才能给靶向细胞的细胞核提供具有治疗意义的剂量。当硼在细胞核中时剂量最高。硼 - 10俘获中子后,细胞核吸收的比能也有广泛分布。例如,当应用10⁸ - 10¹⁰个硼 - 10/核时,分析细胞核的比能从0戈瑞变化到约7戈瑞。这些变化是由于俘获过程的随机性。一些氦或锂离子径迹穿过细胞核中心传递大量能量,一些只穿过较小部分传递少量能量,有时细胞核根本未被击中。这些结果是在应用相关中子注量(2 - 5×10¹² n/cm²)时获得的。增加中子注量会因硼和氮的俘获而产生更高剂量,但为了提高靶向肿瘤细胞剂量与正常细胞剂量的比值,必须增加靶向细胞中硼 - 10原子的数量和/或将硼置于细胞核中。